The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...

The proteinase k market is expected to reach approximately USD 30.2 million in 2025 and expand to around USD 48.2 million by 2035, reflecting a compound annual growth rate (CAGR) of 4.8% over the ...

Whippany: Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi, a recombinant DNA-derived, ...

The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years. Advancements in genetic ...

One of the greatest transformations in modern medicine arguably began with a corned beef sandwich.It was the late 1960s, and ...

Not intended for media outside the U.S. WHIPPANY, N.J., May 19, 2025--(BUSINESS WIRE)--Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi ®, a recombinant DNA-derived, ...

A new study published in Physical Review Letters has introduced a new form of the classic Ising model that, by incorporating ...

Jivi first received FDA approval in August 2018. The approval was for use in previously treated adults aged 12 and older who have hemophilia A. The uses included on-demand treatment and control of ...

I traveled to the iconic Asilomar Conference Grounds in Monterey Bay as one of 50 “Next Generation Leaders” invited to take ...

HHS Secretary Robert F. Kennedy Jr.'s probe into mifepristone was fueled by a flawed analysis of insurance claims from a ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and ...

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.